RxDoctor Payments Data

Cesar Morales, PA

Physician Assistant · El Paso, TXNPI 1205368586

Payments from drug & device makers

$757in general payments, 2019–2025

Across 25 payments — averaging $30.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$210
  • E.r. Squibb & Sons, L.L.C.$124
  • Asahi Intecc USA, Inc.$92
  • Lilly USA, LLC$80
  • Amgen$71
  • Novo Nordisk$45
  • plus $136 from 6 others

What the payments were for

  • Food & beverage$757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$563
Medicare patients
28
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide260$276,197
TrulicityDulaglutide116$192,170
JardianceEmpagliflozin106$153,863
JanuviaSitagliptin Phosphate80$112,533
MounjaroTirzepatide60$64,314
EliquisApixaban81$57,876
RybelsusSemaglutide19$25,515
JanumetSitagliptin Phos/Metformin Hcl22$23,996
ProliaDenosumab12$21,473
Lantus SolostarInsulin Glargine,hum.Rec.Anlog116$15,083
Repatha SureclickEvolocumab13$14,583
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$13,481
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,477
Omega-3 Acid Ethyl Esters75$9,034
Diclofenac Sodium90$7,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$45$301,711279 claims
Lilly USA, LLCTrulicity, Mounjaro$80$256,484176 claims
Boehringer IngelheimJardiance$23$153,863106 claims
MerckJanuvia, Janumet$15$136,529102 claims
PfizerEliquis$14$57,87681 claims
AmgenProlia$71$21,47312 claims
GSKTrelegy Ellipta$34$11,47718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →